Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
source : Www.vynetherapeutics.com save search
SEC Filing: Form 4
Published: 2023-07-05 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: -0.49%
H: 3.72%
C: 3.47%
SEC Filing: Form 4
Published: 2023-06-02 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: -1.31%
H: 6.64%
C: 0.66%
VYNE Investor Relations Presentation
Published: 2023-05-15 (Crawled : 16:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: 0.14%
H: 6.56%
C: 6.08%
presentation
SEC Filing: Form 10-Q
Published: 2023-05-11 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: 0.0%
H: 12.54%
C: 2.01%
SEC Filing: Form 8-K
Published: 2023-05-11 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: 0.0%
H: 12.54%
C: 2.01%
SEC Filing: Form 8-K
Published: 2023-05-01 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: 0.0%
H: 18.63%
C: 14.83%
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
Published: 2023-05-01 (Crawled : 12:20) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: 0.0%
H: 18.63%
C: 14.83%
vyn202 candidate treatment therapeutics potential
VYNE Investor Relations Presentation
Published: 2023-04-20 (Crawled : 12:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: -7.17%
H: 9.9%
C: 5.8%
presentation
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
Published: 2023-04-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: 7.03%
H: 50.75%
C: 33.13%
vyn201 positive fibrosis preclinical therapeutics
SEC Filing: Form 4
Published: 2023-04-04 (Crawled : 22:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: -1.01%
H: 6.83%
C: -2.43%
VYNE Investor Relations Presentation
Published: 2023-03-30 (Crawled : 12:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: 2.5%
H: 13.53%
C: 13.53%
presentation
SEC Filing: Form 4
Published: 2023-03-22 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: -0.74%
H: 0.37%
C: -5.95%
VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference
Published: 2023-03-22 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: -0.74%
H: 0.37%
C: -5.95%
conference disease therapeutics
SEC Filing: Form 10-K
Published: 2023-03-14 (Crawled : 22:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: 5.39%
H: 2.71%
C: -5.12%
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update
Published: 2023-03-09 (Crawled : 23:00) - vynetherapeutics.com
DERM | $5.69 14.49% 12.65% 320K
|
|
| O: -3.33%
H: 6.9%
C: 3.45%
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: -1.31%
H: 1.32%
C: -0.66%
therapeutics financial update results
SEC Filing: Form 8-K
Published: 2023-03-09 (Crawled : 22:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: -1.31%
H: 1.32%
C: -0.66%
VYNE Investor Relations Presentation
Published: 2023-03-01 (Crawled : 14:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: -9.7%
presentation
SEC Filing: Form 8-K
Published: 2023-02-28 (Crawled : 22:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: -0.37%
H: 0.97%
C: -0.08%
VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
Published: 2023-02-22 (Crawled : 13:20) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: -0.29%
H: 1.39%
C: -0.88%
care conference health therapeutics
VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201
Published: 2023-02-15 (Crawled : 14:00) - vynetherapeutics.com
VYNE | $3.39 0.3% 0.29% 30K
|
Health Technology
|
| O: 2.0%
H: 11.48%
C: -1.68%
vyn201 trial therapeutics positive
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
ZVSA | $2.03 3179.48% 96.95% 330K
|
CHSN | $4.89 68.63% 45.9% 5.7M
|
ANY M | $1.72 60.75% 37.79% 26M
|
Technology Services
VCXA | News 0 d | $15.88 60.57% 37.72% 82K
|
CNET | News | $1.12 60.0% 37.5% 3.8M
|
Commercial Services
MFH | $1.62 37.29% 27.16% 6.5M
|
Technology Services
AIHS | $0.4389 37.16% 27.09% 230K
|
Finance
KALA | $8.83 36.06% 26.5% 2.7M
|
Health Technology
JNVR | $1.53 29.66% 21.33% 2.8M
|
WHLR 4 | $0.3532 26.14% 20.72% 14M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.